Navigation Links
Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results
Date:5/13/2009

ties and the commercialization of all gastrin-based therapeutic products worldwide.

In August 2008, Transition and its collaboration partner Lilly initiated a Phase II trial evaluating TT-223 in type 2 diabetes patients receiving metformin and/or thiazolidinediones (TZDs) which completed enrolling patients in February 2009.

On March 23, 2009, Transition announced the initiation of a Phase Ib clinical study of TT-223 in combination with a GLP-1 analogue in patients with type 2 diabetes. The study is a randomized, double-blind, placebo-controlled study in approximately 140 patients to evaluate the safety, tolerability and efficacy of daily TT-223 treatments in combination with weekly administrations of GLP-1 analogue, for a combination treatment period of 4 weeks with a 5-month follow-up.

Juvenile Diabetes Research Foundation ("JDRF")

In September 2006, the Company entered into an agreement with the JDRF to support the clinical development of TT-223 in combination with GLP1 analogues for the treatment of type 1 diabetes over a two year period.

The original objective of the JDRF funding was to support efforts towards the development of an effective gastrin-based therapy for diabetes. The research funding used to date has supported meaningful work that has advanced the TT-223 combination therapies into position to begin clinical studies. Lilly will be fully supporting this clinical development work not only through financial resources, but through their expertise and specialized clinical development groups. With this in mind, Transition and the JDRF agreed that it would be reasonable for the JDRF to reassign financial resources earmarked for development of gastrin-based therapies to another worthy research program.

Accordingly, on April 3, 2009, the Company terminated the agreement with the JDRF and paid $441,455 (US$350,000) which represents the total amounts owing to the JDRF under the terms of the agre
'/>"/>

SOURCE Transition Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2009 Financial Results on Wednesday, May 13th, at 4:30 P.M. EST
2. TouchPointCare Introduces TPC Transition Home to Help Hospitals Reduce Unplanned Readmissions
3. Transition From Home to Hospital Rarely Seamless
4. iMedica Launches Transition™, a New, Streamlined EHR That Breaks Down the Barriers to Physician Adoption and Use
5. HCSC Discusses the Controversial ICD-10 Transition at the 2009 HIMSS Conference
6. The Quantum Group Announces Transition to Continental Stock Transfer
7. iMedica and Imagetek Team up to Ease Transition to Paperless Medical Practice
8. iMedica and Imagetek Team Up to Ease Transition to Paperless Medical Practice
9. Northeastern Hospital to Transition to Northeastern Ambulatory Care Center
10. Transition Therapeutics Announces Initiation of a Phase Ib Clinical Study of TT-223 in combination with a GLP-1 analogue in Patients with Type 2 Diabetes
11. Mylan Announces Transition of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Spring is the perfect time to get ... with whole foods to weather perfect for outdoor exercise. ... the nutrition experts at Brilliant Nutrition highlight five spring ... 1. Eating Locally, With the abundance of fresh farmers' ... explore, spring is a great time to take advantage ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Standard advice ... test-drive and little else. However given industry’s less than ... to shoppers via the internet, Consumer Mattress Reports sets ... “ Choosing The Best Mattress .” , This article ... tips and suggestions that may not be readily apparent ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Patients of Dr. ... who have lost teeth due to gum disease and would ... for gum disease treatment with laser gum surgery. ... have the highest success rate out of all tooth replacement ... is a relatively new procedure cleared by the Food and ...
(Date:5/21/2013)... BOSTON (May 21, 2013) Prostaglandin analogues (PGAs), drugs ... of treatment for people with glaucoma, but their use ... with blurred vision, dryness, changes in eye color and ... that these drugs also cause upper and lower eyelid ... The findings are described in PLOS ONE . ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 HealthSmart continues ... expanding national presence has required the hiring of new ... HealthSmart is pleased to announce that Dawn Powell has ... serving as the Director of Account Management in the ... offices in Irving, Texas. With extensive client management, employee ...
Breaking Medicine News(10 mins):Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 2Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 3Health News:Choosing the Best Mattress Simplified in Consumer Mattress Reports’ Latest Article 2Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2Health News:Glaucoma drug can cause droopy eyelids 2Health News:New Talent Joins the HealthSmart Account Management Team 2
... finds 12-month course of valganciclover wards off ... News) -- Extended antiviral treatment after a lung ... rejection, a new study from Duke University Medical ... in lung transplant recipients is cytomegalovirus (CMV), which ...
... the potentially powerful influence of political pressure on ... that use of a largely unproven mammography screening ... cost. Joshua Fenton, assistant professor in the ... with colleagues from the University of Washington and ...
... to new targets, treatments, researcher says , MONDAY, June 14 ... new regions of the human genome that may be related ... in the June issue of the Archives of ... at risk for the devastating dementia just yet, however. , ...
... around 200,000 people in Sweden have been diagnosed with ... be helped by mechanical heart pumps, reveals a thesis ... a total of 99 patients with life-threatening heart failure ... long-term circulatory support., "Two-thirds of these patients survived," says ...
... Men with this history are more prone to hit and ... -- Men who attempted suicide before age 18 are much ... a study from the Oregon Social Learning Center in Eugene. ... neighborhoods who were assessed annually from ages 10 to 32. ...
... According ... within 6 months. Amgen’s Prolia is the newest product to enter the market. Prolia ... ... to a recent analysis by SDI , a leading healthcare market insight and analytics ...
Cached Medicine News:Health News:Longer Antiviral Therapy Reduces Lung Transplant Complications 2Health News:Use of unproven mammography tool soars with Medicare coverage 2Health News:Scientists Spot More Genes Related to Alzheimer's 2Health News:Teen Boys Who Attempt Suicide More Likely to Abuse as Adults 2Health News:SDI Reports: Roughly Half of Patients Prescribed the Most Popular Osteoporosis Drugs Discontinue Therapy Within 6 Months -- Amgen's Prolia Offers New Dosing Option 2
(Date:5/21/2013)... Md. , May 21, 2013 ... disposable drug-free consumer electronic devices, announced that CEO, ... presenting today to the FDA,s Medical Advisory Committee, ... the company,s products for over the counter sales. ... FDA developed its medical device classification schema," Whelan ...
(Date:5/21/2013)... 21, 2013 Reportlinker.com announces that ... in its catalogue:   ... Optical Coherence Tomography (OCT) ... OBJECTIVES   BCC,s ... offer synopsis of the current and future ...
(Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 /PRNewswire/ ... Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the ... positive Phase 2a study results of dupilumab (SAR231893/REGN668) in ... monoclonal antibody targeting the alpha subunit of the interleukin ... IL-4 and IL-13, drivers of Th2 (Type 2 helper ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7
... N.Y., Dec. 22 Cold Spring Publishing, LLC, announced ... change to Harborside Press, LLC. , In addition, Harborside Press ... over the past year requires a substantial expansion in personnel and ... the new offices of Harborside Press will be located at 37 ...
... , JACKSON, Miss., Dec. 22, 2009 University of ... VISICU e ICU® Program to enhance care of the critically ... in the region to implement the eICU Program, UMHC will serve ... UMHC is using the Philips VISICU eICU Program and ...
Cached Medicine Technology:University of Mississippi Health Care Implements Philips VISICU eICU(R) Program 2University of Mississippi Health Care Implements Philips VISICU eICU(R) Program 3
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Trident Hemispherical Acetabular Shells are a true hemispherical shape designed to achieve press-fit fixation by under-reaming the acetabulum....
For primary and revision cases...
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Medicine Products: